Iovance Biotherapeutics to Present at Upcoming Conferences

About this update from Iovance Biotherapeutics, Inc.

[{"type":"image","alt":"Iovance Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Iovance Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.v3WcxvLExw0gdNQeyFn2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fb47f4fbc477e50ab2663b1d46d1f520","width":300,"height":98}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:","length":348,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"2025 Wells Fargo Healthcare ConferenceFireside Chat: September 5, 2025 at 8:00 a.m. ETBoston, MA","length":98,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":98,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment ConferencePresentation: September 9, 2025 at 11:00 a.m. ETNew York, NY","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":118,"olType":false},{"type":"text","content":"The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.","length":108,"tagName":"p"},{"type":"text","content":"About Iovance Biotherapeutics, Inc.","length":40,"tagName":"p"},{"type":"text","content":"Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may exte...

More updates from Iovance Biotherapeutics, Inc.